Incidence of Hypogammaglobulinemia in Patients Receiving Rituximab and the Use of Intravenous Immunoglobulin for Recurrent Infections

Maloney, 1997, IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma, J Clin Oncol, 15, 3266, 10.1200/JCO.1997.15.10.3266

Maloney, 1997, IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma, Blood, 90, 2188, 10.1182/blood.V90.6.2188

McLaughlin, 1998, Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program, J Clin Oncol, 16, 2825, 10.1200/JCO.1998.16.8.2825

Coiffier, 2002, CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma, N Engl J Med, 346, 235, 10.1056/NEJMoa011795

Feugier, 2005, Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte, J Clin Oncol, 23, 4117, 10.1200/JCO.2005.09.131

Pfreundschuh, 2006, Chop-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group, Lancet Oncol, 7, 379, 10.1016/S1470-2045(06)70664-7

Hallek, 2010, Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial, Lancet, 376, 1164, 10.1016/S0140-6736(10)61381-5

Robak, 2010, Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia, J Clin Oncol, 28, 1756, 10.1200/JCO.2009.26.4556

Mease, 2008, Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: results of the dose-ranging assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) trial, J Rheumatol, 35, 20

Mangel, 2004, Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis, Ann Oncol, 15, 283, 10.1093/annonc/mdh069

Brugger, 2004, Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study, Ann Oncol, 15, 1691, 10.1093/annonc/mdh425

Horwitz, 2004, Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma, Blood, 103, 777, 10.1182/blood-2003-04-1257

Neumann, 2006, Rituximab long-term maintenance therapy after autologous stem cell transplantation in patients with B-cell non-Hodgkin's lymphoma, Ann Hematol, 85, 530, 10.1007/s00277-006-0113-5

Habermann, 2006, Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma, J Clin Oncol, 24, 3121, 10.1200/JCO.2005.05.1003

Haioun, 2009, Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma, Ann Oncol, 20, 1985, 10.1093/annonc/mdp237

Hicks, 2009, Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma, Bone Marrow Transplant, 43, 701, 10.1038/bmt.2008.382

Kenkre, 2011, Maintenance rituximab following induction chemoimmunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology Network, Leuk Lymphoma, 52, 1675, 10.3109/10428194.2011.580404

Chaiwatanatorn, 2003, Delayed-onset neutropenia associated with rituximab therapy, Br J Haematol, 121, 913, 10.1046/j.1365-2141.2003.04385.x

Tsutsumi, 2005, Reactivation of hepatitis B virus with rituximab, Expert Opin Drug Saf, 4, 599, 10.1517/14740338.4.3.599

Fogarty, 2006, Three cases of activation of cutaneous squamous-cell carcinoma during treatment with prolonged administration of rituximab, Clin Oncol (R Coll Radiol), 18, 155, 10.1016/j.clon.2005.11.015

Carson, 2009, Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the Research on Adverse Drug Events and Reports (RADAR) Project, Lancet Oncol, 10, 816, 10.1016/S1470-2045(09)70161-5

Cooper, 2010, The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases, Br J Haematol, 149, 3, 10.1111/j.1365-2141.2010.08076.x

Nishio, 2006, Hypogammaglobulinemia with a selective delayed recovery in memory B cells and an impaired isotype expression after rituximab administration as an adjuvant to autologous stem cell transplantation for non-Hodgkin lymphoma, Eur J Haematol, 77, 226, 10.1111/j.1600-0609.2006.00693.x

Cabanillas, 2006, High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: a frequently unrecognized and easily treatable complication, Ann Oncol, 17, 1424, 10.1093/annonc/mdl141

Arber, 2007, Septic polyarthritis with Ureaplasma urealyticum in a patient with prolonged agammaglobulinemia and B-cell aplasia after allogeneic HSCT and rituximab pretreatment, Bone Marrow Transplant, 40, 597, 10.1038/sj.bmt.1705766

Cooper, 2009, Repeated courses of rituximab for autoimmune cytopenias may precipitate profound hypogammaglobulinaemia requiring replacement intravenous immunoglobulin, Br J Haematol, 146, 120, 10.1111/j.1365-2141.2009.07715.x

Diwakar, 2010, Does rituximab aggravate pre-existing hypogammaglobulinaemia?, J Clin Pathol, 63, 275, 10.1136/jcp.2009.068940

Sclove

Orange, 2005, Position statement on the appropriate use of intravenously administered immunoglobulin (IVIG), American Acad of Allergy, Asthma And Immunol

de Gracia, 2004, Immunoglobulin therapy to control lung damage in patients with common variable immunodeficiency, Int Immunopharmacol, 4, 745, 10.1016/j.intimp.2004.02.011

Roifman, 1987, High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinaemia and chronic lung disease, Lancet, I, 1075, 10.1016/S0140-6736(87)90494-6

Quartier, 1999, Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective survey of 31 patients, J Pediatr, 134, 589, 10.1016/S0022-3476(99)70246-5

Zelenetz, 2011, Non-Hodgkin's lymphomas, J Natl Compr Cancer Netw JNCCN, 9, 484, 10.6004/jnccn.2011.0046

Aksoy, 2009, Infectious complications of rituximab in patients with lymphoma during maintenance therapy: a systematic review and meta-analysis, Leuk Lymphoma, 50, 357, 10.1080/10428190902730219

Buckley, 1991, The use of intravenous immune globulin in immunodeficiency diseases, N Engl J Med, 325, 110, 10.1056/NEJM199107113250207

Morrison, 2001, Impact of therapy with chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011, J Clin Oncol, 19, 3611, 10.1200/JCO.2001.19.16.3611

Byrd, 1999, Herpes virus infections occur frequently following treatment with fludarabine: results of a prospective natural history study, Br J Haematol, 105, 445, 10.1111/j.1365-2141.1999.01364.x